Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091238 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL7847798 | 0.71 | — | — | |
| SCHEMBL29795443 | 0.71 | — | — | |
| SCHEMBL4049251 | 0.71 | — | — | |
| SCHEMBL2703095 | 0.71 | — | — | |
| SCHEMBL27806916 | 0.71 | — | — | |
| SCHEMBL28822656 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL23706398 | 0.50 | — | — | |
| Hydrochloric Acid SCHEMBL2962244 | 0.50 | — | — | |
| Hydrochloric Acid SCHEMBL22685 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| EP-3664823-B1 | COMPOSITION FOR USE IN PREVENTING OR TREATING AN ENTEROCOCCAL BLOOD STREAM INFECTION | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4746909-A2 | MODULATION OF MYELOID FCgamma RECEPTOR DEPLETION | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748449-A2 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107393-A2 | AAV CAPSID MODIFICATIONS THAT REDUCE IMMUNOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3946489-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2022020616-A1 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-11229703-B2 | Radiotherapy improvements | NOXOPHARM LIMITED (AU) | 2022-01-25 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |